I-MAB (IMAB) has released an update.
I-MAB Biopharma US Limited has entered into a six-month secondment agreement with ABio-X Holdings, Inc., effective July 15, 2024, where Sean Xi-Yong Fu will serve as interim CEO for I-MAB. The agreement outlines that Fu remains an employee of ABio-X with his salary and benefits paid by them, while I-MAB will compensate ABio-X for his services. The agreement may be renewed monthly and includes provisions for automatic termination, responsibilities, and confidentiality.
For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.
